Mitoxantrone clinical trials
Also written Novantrone, CL 232315 and Mitozantrone.
Includes 34 studies of Liposomal Mitoxantrone Hydrochloride and 3 studies of Pegylated Liposomal Mitoxantrone Hydrochloride.
How each study uses Mitoxantrone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Mitoxantrone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Dec 1987 · NOVANTRONE · NDA 019297 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
162 studies that test it; most in 2021 (12)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 1 |
| 1993 | 1 |
| 1994 | 3 |
| 1995 | 2 |
| 1996 | 3 |
| 1997 | 6 |
| 1998 | 3 |
| 1999 | 5 |
| 2000 | 2 |
| 2001 | 6 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 7 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 8 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 35 · Other 130
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (22) · National Cancer Institute (NCI) (13) · Fred Hutchinson Cancer Center (8) · M.D. Anderson Cancer Center (6) · Institute of Hematology & Blood Diseases Hospital, China (6) · University of Washington (5) · Memorial Sloan Kettering Cancer Center (4) · St. Jude Children's Research Hospital (3)
Often tested with
Tested in the same studies.
Cytarabine (48) · Etoposide (35) · Cyclophosphamide (18) · Rituximab (18) · Prednisone (16) · Cladribine (15) · Fludarabine (12) · Vincristine (11)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Mitoxantrone is the comparator. A study of two new drugs counts under both.
- 1Blinatumomab · National Cancer Institute (NCI)
- 1Cyclophosphamide · National Cancer Institute (NCI)
- 1Etoposide · National Cancer Institute (NCI)
- 1Leucovorin · National Cancer Institute (NCI)
- 1Mercaptopurine · National Cancer Institute (NCI)
- 1Pegaspargase · National Cancer Institute (NCI)
- 1Thioguanine · National Cancer Institute (NCI)
- 1Vincristine · National Cancer Institute (NCI)
Reaching primary completion within a year · 6
Studies that test Mitoxantrone.
- Dec 2026Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaPhase 1 · University of Colorado, Denver
- Dec 2026Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot applicable · First Affiliated Hospital Xi'an Jiaotong University
- Feb 2027CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaPhase 1 · Fred Hutchinson Cancer Center
- May 2027VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Oct 2027Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot applicable · The First Affiliated Hospital with Nanjing Medical University
Studies
Open first, then newest update. How each study uses Mitoxantrone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 165
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingPhase 1/2University of WashingtonNCT04797767Written as Mitoxantrone
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingPhase 1Fred Hutchinson Cancer CenterNCT04375631Written as Mitoxantrone
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Mitoxantrone
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Daunorubicin/ Idarubicin /Mitoxantrone
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07490288Written as Liposomal Mitoxantrone
- Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot yet recruitingNot applicableThe First Affiliated Hospital with Nanjing Medical UniversityNCT07389356Written as Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide
- Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer SurgeryNot yet recruitingPhase 4Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07354698Written as mitoxantrone hydrochloride injection
- Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaRecruitingPhase 1University of Colorado, DenverNCT06429449Written as Mitoxantrone
- Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AMLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06758726Written as Mitoxantrone Hydrochloride Liposome combined with BU/Cy
- Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05958719Written as liposomal mitoxantrone
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Mitoxantrone hydrochloride liposome
- Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.RecruitingPhase 2Yizhuo ZhangNCT06514313Written as Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
- VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06447090Written as Mitoxantrone hydrochloride liposome
- Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot yet recruitingNot applicableFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT06385808Written as MTBF regimen
- Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05875428Written as Mitoxantrone Hydrochloride Liposome Injection
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNot applicableThe First Hospital of Jilin UniversityNCT05990985Written as Mitoxantrone hydrochloride liposome injection
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingPhase 2/3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05313958Written as Mitoxantrone
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2Second Affiliated Hospital of Soochow UniversityNCT05857982Written as Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRecruitingPhase 1/2Hui ZengNCT05522192Written as Mitoxantrone liposome
- Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT02553460Written as Mitoxantrone
See all 165 studies that test Mitoxantrone →
Given beside what is tested · 76 — Mitoxantrone is usual care or a partner of the new treatment
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Mitoxantrone
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07831395Written as Liposomal mitoxantrone
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Mitoxantrone Hydrochloride
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Mitoxantrone Hydrochloride
- Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLNot yet recruitingPhase 3Ruijin HospitalNCT07735117Written as Mitoxantrone Hydrochloride Liposome
- SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07725705Written as SHR2554 combined with Liposomal Mitoxantrone
- R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06594640Written as Mitoxantrone Hydrochloride Liposome
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07486479Written as Mitoxantrone Hydrochloride Liposome
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07372352Written as Mitoxantrone Hydrochloride Liposome
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingPhase 1/2Sun Yat-sen UniversityNCT07093710Written as Mitoxantrone Hydrochloride Liposome
- Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Sun Yat-Sen University Cancer CenterNCT07288814Written as Mitoxantrone Hydrochloride Liposome & Enlonstobart
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as Mitoxantrone Hydrochloride Liposome
- Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06621212Written as mitoxantrone hydrochloride liposome
- CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsRecruitingPhase 2Princess Maxima Center for Pediatric OncologyNCT06262438Written as Mitoxantrone
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06892431Written as Mitoxantrone Hydrochloride Liposome
- Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPCRecruitingPhase 2Ming-Yuan ChenNCT06472713Written as Mitoxantrone hydrochloride liposome injection
- Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06621199Written as Mitoxantrone hydrochloride liposome
- Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06489808Written as Mitoxantrone hydrochloride liposome
- Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06434662Written as mitoxantrone hydrochloride liposome
- Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT05823701Written as Liposomal mitoxantrone
Showing 20 of 76.
As the comparator · 13 — what is tested is compared with Mitoxantrone
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02101853Written as Mitoxantrone
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedPhase 3Astellas Pharma IncNCT03182244Written as Mitoxantrone
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingPhase 3University of BirminghamNCT02724163Written as Mitoxantrone
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedPhase 3Technische Universität DresdenNCT02688140Written as Mitoxantrone
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Mitoxantrone
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 3PfizerNCT01564784Written as cytarabine and mitoxantrone
- Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerTerminatedPhase 3ExelixisNCT01522443Written as mitoxantrone
- Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 3PfizerNCT00562965Written as mitoxantrone
- Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)Status unknownPhase 4The First Hospital of Jilin UniversityNCT03026842Written as Mitoxantrone, Cytarabine
- Study of Irofulven in Patients With Hormone-refractory Prostate CancerCompletedPhase 2Eisai Inc.NCT00124566Written as Mitoxantrone
- S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyCompletedPhase 3SWOG Cancer Research NetworkNCT00004001Written as mitoxantrone
- Taxotere Prostate Cancer New Indication Registration Trial in ChinaCompletedPhase 3SanofiNCT00436839Written as Mitoxantrone
- XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerCompletedPhase 3SanofiNCT00417079Written as mitoxantrone
Codes
What other systems call Mitoxantrone · ClinicalTrials.gg INT007848
- MeSH (NLM) D008942MitoxantroneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BZ114NVM5PMITOXANTRONEConfirmed FDA, NLM, Wikidata
- RxNorm 7005Confirmed FDA, Wikidata
- Wikidata Q239426mitoxantroneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62050MitoxantroneOne source FDA
- DrugBank DB01204One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008942 | Mitoxantrone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BZ114NVM5P | MITOXANTRONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7005 | — | Confirmed FDA, Wikidata |
| Wikidata | Q239426 | mitoxantrone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62050 | Mitoxantrone | One source FDA |
| DrugBank | DB01204 | — | One source Wikidata |
Also registered as mitoxantrone hydrochloride (UNII U6USW86RD0 · RxNorm 203129).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.